{"id":5402,"date":"2021-09-14T13:44:52","date_gmt":"2021-09-14T11:44:52","guid":{"rendered":"https:\/\/www.cenata.de\/?p=5402"},"modified":"2022-05-02T08:51:58","modified_gmt":"2022-05-02T07:51:58","slug":"determination-of-the-fetal-rhd-status-from-maternal-blood","status":"publish","type":"post","link":"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/","title":{"rendered":"Determination of the fetal RhD status from maternal blood"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"5402\" class=\"elementor elementor-5402\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-8e44267 elementor-section-stretched elementor-hidden-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"8e44267\" data-element_type=\"section\" data-e-type=\"section\" data-settings='{\"stretch_section\":\"section-stretched\"}'>\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-609bb9f elementor-hidden-mobile\" data-id=\"609bb9f\" data-element_type=\"column\" data-e-type=\"column\" data-settings='{\"background_background\":\"classic\"}'>\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-537879e elementor-nav-menu__align-end elementor-nav-menu--dropdown-tablet elementor-nav-menu__text-align-aside elementor-nav-menu--toggle elementor-nav-menu--burger elementor-widget elementor-widget-nav-menu\" data-id=\"537879e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings='{\"layout\":\"vertical\",\"submenu_icon\":{\"value\":\"&lt;i class=\\\"\\\" aria-hidden=\\\"true\\\"&gt;&lt;\\\/i&gt;\",\"library\":\"\"},\"toggle\":\"burger\"}' data-widget_type=\"nav-menu.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<nav aria-label=\"Menu\" class=\"elementor-nav-menu--main elementor-nav-menu__container elementor-nav-menu--layout-vertical e--pointer-background e--animation-fade\">\n\t\t\t\t<ul id=\"menu-1-537879e\" class=\"elementor-nav-menu sm-vertical\"><li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-28005\"><a href=\"https:\/\/www.cenata.de\/en\/about-cenata\/\" class=\"elementor-item menu-link\">Team Cenata<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-23127\"><a href=\"https:\/\/www.cenata.de\/en\/quality-management\/\" class=\"elementor-item menu-link\">Quality Management<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-23306\"><a href=\"https:\/\/www.cenata.de\/en\/news-2\/\" class=\"elementor-item menu-link\">Latest news<\/a><\/li>\n<\/ul>\t\t\t<\/nav>\n\t\t\t\t\t<div class=\"elementor-menu-toggle\" role=\"button\" tabindex=\"0\" aria-label=\"Menu Toggle\" aria-expanded=\"false\">\n\t\t\t<i aria-hidden=\"true\" role=\"presentation\" class=\"elementor-menu-toggle__icon--open eicon-menu-bar\"><\/i><i aria-hidden=\"true\" role=\"presentation\" class=\"elementor-menu-toggle__icon--close eicon-close\"><\/i>\t\t<\/div>\n\t\t\t\t\t<nav class=\"elementor-nav-menu--dropdown elementor-nav-menu__container\" aria-hidden=\"true\">\n\t\t\t\t<ul id=\"menu-2-537879e\" class=\"elementor-nav-menu sm-vertical\"><li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-28005\"><a href=\"https:\/\/www.cenata.de\/en\/about-cenata\/\" class=\"elementor-item menu-link\" tabindex=\"-1\">Team Cenata<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-23127\"><a href=\"https:\/\/www.cenata.de\/en\/quality-management\/\" class=\"elementor-item menu-link\" tabindex=\"-1\">Quality Management<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-23306\"><a href=\"https:\/\/www.cenata.de\/en\/news-2\/\" class=\"elementor-item menu-link\" tabindex=\"-1\">Latest news<\/a><\/li>\n<\/ul>\t\t\t<\/nav>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-2682c70\" data-id=\"2682c70\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-177989a elementor-widget elementor-widget-heading\" data-id=\"177989a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Determination of the fetal RhD status from maternal blood<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e8a113b elementor-widget elementor-widget-text-editor\" data-id=\"e8a113b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\">14. September 2021<\/header><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><\/header><\/header>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-32cf1d9 elementor-widget elementor-widget-text-editor\" data-id=\"32cf1d9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><div class=\"entry-content\"><p>In Europe around 17% of all pregnant women are RhD-negative. Since the beginning of the 1990s, these women have been receiving RhD prophylaxis in the 28th to 30th week of pregnancy in addition to the targeted postpartum administration. This prenatal Rh prophylaxis, which is usually carried out independently of the RhD status of the fetus, reduces the risk of Rh sensitization from 1 &ndash; 2% to 0.2 &ndash; 0.3%&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-1\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-1\">1<\/a><\/sup>.<br>With the Rhesus&nbsp;<a class=\"encyclopedia\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\">NIPT<\/a>&nbsp;it is now possible to determine the&nbsp;<a class=\"encyclopedia\" title=\"Relating to the unborn child\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\">fetal<\/a>&nbsp;RhD status prenatally non-invasively from maternal blood<sup class=\"footnote\"><a id=\"fnref-5402-2\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-2\">2<\/a><\/sup>. Unnecessary anti-D immunoglobulin treatment, which carries at least a theoretical risk of infection, can be avoided.<\/p><p><strong>Test reliability<\/strong><br>The quantitative PCR test used for&nbsp;<a href=\"https:\/\/www.cenata.de\/en\/test-procedure\/\">Rhesus NIPT<\/a>&nbsp;examines the three exons 5, 7 and 10 of the&nbsp;<em>RHD<\/em>&nbsp;gene. This achieves a high level of reliability with a sensitivity of 99.93% and a specificity of 99.6%&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-3\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-3\">3<\/a><\/sup>.<\/p><p>False positive findings are possible due to &ldquo;silent alleles&rdquo;, which are genes without a real function. In such cases, although the fetus was actually RhD-negative, the test results would mean that Rh prophylaxis would be given unnecessarily. This occurs in approx. 0.4% of cases&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-4\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-4\">4<\/a><\/sup>. Without the use of non-invasive <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> blood group testing, however, Rh prophylaxis would have been given anyway.<\/p><p>False negative results are possible, due to factors such as insufficient cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a>&nbsp;<a class=\"encyclopedia\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\">DNA<\/a>&nbsp;in the mother&rsquo;s blood. Since the amount of cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" class=\"encyclopedia\">DNA<\/a> increases as the pregnancy progresses, it is recommended that the Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> is carried out from 19 + 0 weeks of gestation onwards. If a non-invasive prenatal test is performed (e.g. the Harmony&reg; Test), and the <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> fraction of the blood is determined to be at least 4%, the <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> Rhesus status can also be determined from the 12th week of pregnancy. Overall, the false negative rate is approximately 1 out of 2,000 tests. In this case, a required prenatal Rh prophylaxis would not be administered. Given the generally low immunization risk during pregnancy (no more than 1-2% risk per pregnancy with an RhD-positive fetus), this proportion of false negative results is considered acceptable.<\/p><p>In the opinion of the German &bdquo;Institute for Quality and Efficiency in Health Care&rdquo; (IQWiG), the standard administration of Rh prophylaxis and targeted prophylaxis after testing with Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> give equivalent protective effects, because false negative results are also occasionally found in blood testing during childbirth&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-5\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-5\">5<\/a><\/sup>.<\/p><p><strong>Test procedure<\/strong><br>The Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> can be carried out from gestational week 11 + 0 onwards. To exclude false negative results at best, we recommend doing the Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> from 19 + 0 weeks of gestation onwards. For testing we need 7.5mL of blood provided in an EDTA blood tube. In this tube, the cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" class=\"encyclopedia\">DNA<\/a> is stable for 5 days at room temperature. The Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> test results will usually be sent to you within a week.<\/p><p>Please contact us to discuss pricing. Further information for your patients can be found on our&nbsp;<a href=\"https:\/\/www.cenata.de\/web2016\/wp-content\/uploads\/2021\/09\/Flyer_Rhesus-NIPT_EN_.pdf\">flyer<\/a>. To order sample collection kits and flyer please use our&nbsp;<a href=\"https:\/\/www.cenata.de\/en\/services\/contact\/\">contact form<\/a>. If you have any questions, please do not hesitate to contact us at +49 7071 565 44-430.<\/p><div id=\"footnotes-5402\" class=\"footnotes\"><div class=\"footnotedivider\">&nbsp;<\/div><ol><li id=\"fn-5402-1\">Schulze S und Mund M, Frauenarzt 12\/2020, 815-818&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-1\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-2\">Legler TJ: <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">Fetal<\/a>e molekulargenetische Blutgruppenbestimmung aus m&uuml;tterlichem Plasma. Transfusionsmedizin 2014;4:73-78&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-2\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-3\">Legler TJ et al, Arch Gynecol Obstet 2021 Apr 9. doi: 10.1007\/s00404-021-06055-1&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-3\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-4\">Legler TJ: <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">Fetal<\/a>e molekulargenetische Blutgruppenbestimmung aus m&uuml;tterlichem Plasma. Transfusionsmedizin 2014;4:73-78&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-4\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-5\">Institut f&uuml;r Qualit&auml;t und Wirtschaftlichkeit im Gesundheitswesen, www.iqwig.de\/projekte\/d16-01.html&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-5\">&#8617;<\/a><\/span><\/li><\/ol><\/div><\/div><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><\/header><\/header>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-fac437f elementor-section-stretched elementor-hidden-desktop elementor-hidden-tablet elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"fac437f\" data-element_type=\"section\" data-e-type=\"section\" data-settings='{\"stretch_section\":\"section-stretched\"}'>\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1978a5a\" data-id=\"1978a5a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-93b088e elementor-widget elementor-widget-heading\" data-id=\"93b088e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Determination of the fetal RhD status from maternal blood<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-280f9d4 elementor-widget elementor-widget-text-editor\" data-id=\"280f9d4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\">14. September 2021<\/header><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><\/header><\/header><\/header><\/header><\/header>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-47a5b9f elementor-widget elementor-widget-text-editor\" data-id=\"47a5b9f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><div class=\"entry-content\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><header class=\"entry-content-header\"><div class=\"entry-content\"><p>In Europe around 17% of all pregnant women are RhD-negative. Since the beginning of the 1990s, these women have been receiving RhD prophylaxis in the 28th to 30th week of pregnancy in addition to the targeted postpartum administration. This prenatal Rh prophylaxis, which is usually carried out independently of the RhD status of the fetus, reduces the risk of Rh sensitization from 1 &ndash; 2% to 0.2 &ndash; 0.3%&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-1\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-1\">1<\/a><\/sup>.<br>With the Rhesus&nbsp;<a class=\"encyclopedia\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\">NIPT<\/a>&nbsp;it is now possible to determine the&nbsp;<a class=\"encyclopedia\" title=\"Relating to the unborn child\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\">fetal<\/a>&nbsp;RhD status prenatally non-invasively from maternal blood<sup class=\"footnote\"><a id=\"fnref-5402-2\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-2\">2<\/a><\/sup>. Unnecessary anti-D immunoglobulin treatment, which carries at least a theoretical risk of infection, can be avoided.<\/p><p><strong>Test reliability<\/strong><br>The quantitative PCR test used for&nbsp;<a href=\"https:\/\/www.cenata.de\/en\/test-procedure\/\">Rhesus NIPT<\/a>&nbsp;examines the three exons 5, 7 and 10 of the&nbsp;<em>RHD<\/em>&nbsp;gene. This achieves a high level of reliability with a sensitivity of 99.93% and a specificity of 99.6%&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-3\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-3\">3<\/a><\/sup>.<\/p><p>False positive findings are possible due to &ldquo;silent alleles&rdquo;, which are genes without a real function. In such cases, although the fetus was actually RhD-negative, the test results would mean that Rh prophylaxis would be given unnecessarily. This occurs in approx. 0.4% of cases&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-4\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-4\">4<\/a><\/sup>. Without the use of non-invasive <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> blood group testing, however, Rh prophylaxis would have been given anyway.<\/p><p>False negative results are possible, due to factors such as insufficient cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a>&nbsp;<a class=\"encyclopedia\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\">DNA<\/a>&nbsp;in the mother&rsquo;s blood. Since the amount of cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" class=\"encyclopedia\">DNA<\/a> increases as the pregnancy progresses, it is recommended that the Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> is carried out from 19 + 0 weeks of gestation onwards. If a non-invasive prenatal test is performed (e.g. the Harmony&reg; Test), and the <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> fraction of the blood is determined to be at least 4%, the <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> Rhesus status can also be determined from the 12th week of pregnancy. Overall, the false negative rate is approximately 1 out of 2,000 tests. In this case, a required prenatal Rh prophylaxis would not be administered. Given the generally low immunization risk during pregnancy (no more than 1-2% risk per pregnancy with an RhD-positive fetus), this proportion of false negative results is considered acceptable.<\/p><p>In the opinion of the German &bdquo;Institute for Quality and Efficiency in Health Care&rdquo; (IQWiG), the standard administration of Rh prophylaxis and targeted prophylaxis after testing with Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> give equivalent protective effects, because false negative results are also occasionally found in blood testing during childbirth&nbsp;<sup class=\"footnote\"><a id=\"fnref-5402-5\" href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fn-5402-5\">5<\/a><\/sup>.<\/p><p><strong>Test procedure<\/strong><br>The Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> can be carried out from gestational week 11 + 0 onwards. To exclude false negative results at best, we recommend doing the Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> from 19 + 0 weeks of gestation onwards. For testing we need 7.5mL of blood provided in an EDTA blood tube. In this tube, the cell-free <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">fetal<\/a> <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/dna\/\" target=\"_self\" title=\"Deoxyribonucleic acid: biomolecule and carrier of genetic information\" class=\"encyclopedia\">DNA<\/a> is stable for 5 days at room temperature. The Rhesus <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/nipt\/\" target=\"_self\" title=\"Non-invasive prenatal tests are molecular genetic analyses in prenatal diagnostics to detect fetal chromosomal anomalies from the maternal blood, avoiding the risk of miscarriage inherent in more invasive methods.\" class=\"encyclopedia\">NIPT<\/a> test results will usually be sent to you within a week.<\/p><p>Please contact us to discuss pricing. Further information for your patients can be found on our&nbsp;<a href=\"https:\/\/www.cenata.de\/web2016\/wp-content\/uploads\/2021\/09\/Flyer_Rhesus-NIPT_EN_.pdf\">flyer<\/a>. To order sample collection kits and flyer please use our&nbsp;<a href=\"https:\/\/www.cenata.de\/en\/services\/contact\/\">contact form<\/a>. If you have any questions, please do not hesitate to contact us at +49 7071 565 44-430.<\/p><div id=\"footnotes-5402\" class=\"footnotes\"><div class=\"footnotedivider\">&nbsp;<\/div><ol><li id=\"fn-5402-1\">Schulze S und Mund M, Frauenarzt 12\/2020, 815-818&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-1\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-2\">Legler TJ: <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">Fetal<\/a>e molekulargenetische Blutgruppenbestimmung aus m&uuml;tterlichem Plasma. Transfusionsmedizin 2014;4:73-78&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-2\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-3\">Legler TJ et al, Arch Gynecol Obstet 2021 Apr 9. doi: 10.1007\/s00404-021-06055-1&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-3\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-4\">Legler TJ: <a href=\"https:\/\/www.cenata.de\/en\/encyclopedia\/fetal\/\" target=\"_self\" title=\"Relating to the unborn child\" class=\"encyclopedia\">Fetal<\/a>e molekulargenetische Blutgruppenbestimmung aus m&uuml;tterlichem Plasma. Transfusionsmedizin 2014;4:73-78&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-4\">&#8617;<\/a><\/span><\/li><li id=\"fn-5402-5\">Institut f&uuml;r Qualit&auml;t und Wirtschaftlichkeit im Gesundheitswesen, www.iqwig.de\/projekte\/d16-01.html&nbsp;<span class=\"footnotereverse\"><a href=\"https:\/\/www.cenata.de\/en\/determination-of-the-fetal-rhd-status-from-maternal-blood\/#fnref-5402-5\">&#8617;<\/a><\/span><\/li><\/ol><\/div><\/div><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><\/header><\/header><\/div><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><footer class=\"entry-footer\"><\/footer><\/header><\/header><\/header><\/header><\/header><\/header><\/header><\/header>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Determination of the fetal RhD status from maternal blood 14. September 2021 In Europe around 17% of all pregnant women are RhD-negative. Since the beginning of the 1990s, these women have been receiving RhD prophylaxis in the 28th to 30th week of pregnancy in addition to the targeted postpartum administration. This prenatal Rh prophylaxis, which [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5402","post","type-post","status-publish","format-standard","hentry","category-unkategorisiert"],"_links":{"self":[{"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/posts\/5402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/comments?post=5402"}],"version-history":[{"count":7,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/posts\/5402\/revisions"}],"predecessor-version":[{"id":24981,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/posts\/5402\/revisions\/24981"}],"wp:attachment":[{"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/media?parent=5402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/categories?post=5402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cenata.de\/en\/wp-json\/wp\/v2\/tags?post=5402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}